Arpeggio Biosciences
Arpeggio Bio: AI-driven drug development targeting transcription factors for hard-to-treat diseases.
Arpeggio Bio: AI-driven drug development targeting transcription factors for hard-to-treat diseases.
Arpeggio Bio, founded with a mission to revolutionize drug discovery, focuses on developing drugs targeting transcription factors using AI and high-throughput RNA-sequencing. The company aims to address hard-to-treat diseases by leveraging network biology rather than single-target approaches. Arpeggio Bio's innovative platform has enabled the development of treatments for "undruggable" proteins such as NRF2, TEAD, and GPX4, with a lead program advancing towards a DC for IO-resistant melanoma. Their market focus includes rare diseases and chronic inflammation.
Notable affiliations include partnerships with Johnson & Johnson and FORMA Therapeutics, which have validated Arpeggio Bio's platform through significant Phase I successes. With $20 million in venture funding, the company has made substantial progress in its drug development pipeline. Arpeggio Bio's impact is evident in its rapid advancements and the potential to transform treatment paradigms for challenging diseases through its AI-driven, network biology-based approach.
Companies similar to Arpeggio Biosciences include GEn1E Lifesciences, Arbor Biotechnologies, Verge Genomics and Harmonic Discovery.
Arpeggio Biosciences was founded in 2018.
Arpeggio Biosciences' headquarters is located in Boulder, CO, US.
Arpeggio Biosciences' most recent funding round was for $17M (USD) in September 2022.
As of Sep 7, 2022, Arpeggio Biosciences has disclosed funding of $20.4M (USD). Undisclosed round amounts are excluded.
Arpeggio Biosciences has 18 employees as of Feb 5, 2024.
Harmonic Discovery
